These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9624494)

  • 41. Novel extended-spectrum TEM-type beta-lactamase from an Escherichia coli isolate resistant to ceftazidime and susceptible to cephalothin.
    Chanal-Claris C; Sirot D; Bret L; Chatron P; Labia R; Sirot J
    Antimicrob Agents Chemother; 1997 Mar; 41(3):715-6. PubMed ID: 9056022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cloning and sequencing of the gene encoding Toho-2, a class A beta-lactamase preferentially inhibited by tazobactam.
    Ma L; Ishii Y; Ishiguro M; Matsuzawa H; Yamaguchi K
    Antimicrob Agents Chemother; 1998 May; 42(5):1181-6. PubMed ID: 9593147
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Fraile-Ribot PA; Mulet X; Cabot G; Del Barrio-Tofiño E; Juan C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
    Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
    Int J Antimicrob Agents; 2017 Feb; 49(2):239-242. PubMed ID: 27939093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.
    Pohlman JK; Knapp CC; Ludwig MD; Washington JA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):29-33. PubMed ID: 8950526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization and amino acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to beta-lactamase inhibitors.
    Brun T; Péduzzi J; Caniça MM; Paul G; Névot P; Barthélémy M; Labia R
    FEMS Microbiol Lett; 1994 Jul; 120(1-2):111-7. PubMed ID: 8056282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum beta-lactamases.
    Walther-Rasmussen J; Høiby N
    Can J Microbiol; 2004 Mar; 50(3):137-65. PubMed ID: 15105882
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of a novel plasmid-mediated beta-lactamase with chromosomal cephalosporinase characteristics from Klebsiella pneumoniae.
    Tzouvelekis LS; Tzelepi E; Mentis AF; Tsakris A
    J Antimicrob Chemother; 1993 May; 31(5):645-54. PubMed ID: 8335495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor.
    Nishida K; Kunugita C; Uji T; Higashitani F; Hyodo A; Unemi N; Maiti SN; Phillips OA; Spevak P; Atchison KP; Salama SM; Atwal H; Micetich RG
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1895-900. PubMed ID: 10428909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
    Therrien C; Kotra LP; Sanschagrin F; Mobashery S; Levesque RC
    FEBS Lett; 2000 Mar; 470(3):285-92. PubMed ID: 10745083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors.
    Moosdeen F; Keeble J; Williams JD
    Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases.
    Sabbagh Y; Thériault E; Sanschagrin F; Voyer N; Palzkill T; Levesque RC
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2319-25. PubMed ID: 9736556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aztreonam-clavulanic acid synergy does not mean extended-spectrum beta-lactamase in Stenotrophomonas maltophilia.
    Muñoz Bellido JL; García-Rodriguez JA
    J Antimicrob Chemother; 1998 Apr; 41(4):493-4. PubMed ID: 9598782
    [No Abstract]   [Full Text] [Related]  

  • 55. E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates.
    Perilli M; Celenza G; De Santis F; Pellegrini C; Forcella C; Rossolini GM; Stefani S; Amicosante G
    Antimicrob Agents Chemother; 2008 Mar; 52(3):915-9. PubMed ID: 18160520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
    Bethel CR; Taracila M; Shyr T; Thomson JM; Distler AM; Hujer KM; Hujer AM; Endimiani A; Papp-Wallace K; Bonnet R; Bonomo RA
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3465-75. PubMed ID: 21555770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kinetic characterization of GES-22 β-lactamase harboring the M169L clinical mutation.
    Saral A; Leonard DA; Duzgun AO; Cicek AC; June CM; Sandalli C
    J Antibiot (Tokyo); 2016 Dec; 69(12):858-862. PubMed ID: 27168312
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
    Fonseca F; Sarmento AC; Henriques I; Samyn B; van Beeumen J; Domingues P; Domingues MR; Saavedra MJ; Correia A
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4512-4. PubMed ID: 17875998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases.
    Babini GS; Livermore DM
    J Antimicrob Chemother; 2000 Jan; 45(1):105-9. PubMed ID: 10629020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biochemical and genetic characteristics of TEM-29B, a novel extended spectrum beta-lactamase.
    Bou G; Martínez-Beltrán J; Cerveró G; Pérez-Díaz JC
    FEMS Microbiol Lett; 1999 May; 174(1):185-90. PubMed ID: 10234838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.